Solid Tumors with Specific Mutations

- IDH 1/2 mutant
- CCNE1 amplification
- PTEN, PIK3CA
- DNA repair; PI3K/AKT, RAS/RAF/MEK
- NF1, KEAP1, and LKB1
- Loss of SETD2
- NUT fusion oncogene
- HER2-positive

**ETCTN Trials by Disease/Treatment Area: Solid Tumors with Specific Mutations**

- **10129**: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
- **10222**: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors
- **10136**: A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification
- **10221**: Phase I/II Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors
- **10131**: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Expansion: breast, prostate, other solid tumors)
- **9149**: Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors
- **10217**: A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors (Expansion: germline or somatic DDR aberrations; PIK3CA mutant; PTEN loss)
- **10329**: Phase I Sequential Trial of Agents Against DNA Repair (STAR) (Dose escalation: enriched for DDR aberrations; Expansion: Cohort A: BRCA1/2; Cohort B: DDR aberrations)
- **10220**: A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
- **10170**: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
- **10295**: A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination with Etoposide/Platinum in Patients with NUT Carcinoma
- **10346**: A Phase I Study of DS-8201a Pharmacodynamics in Patients with HER2-positive Advanced Solid Tumors

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 16, 2019